Press Release: Wuxi XDC

WuXi XDC Triumphs at the Asia-Pacific Biopharma Excellence Awards 2025, Securing Multiple Top Honors

Singapore |24 March 2025

‍WuXi XDC Cayman Inc. (the “WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, has been recognized as a top pioneer at the Asia-Pacific Biopharma Excellence Awards 2025, winning multiple prestigious accolades. This recognition underscores WuXi XDC’s leadership, innovation, and fully integrated CRDMO platform, empowering global clients from early discovery to commercial manufacturing.

At this year’s awards ceremony in Singapore, WuXi XDC received top honors in the following categories:

• Best ADC CDMO in Asia

• Best ADC CDMO in China

• Best ADC CRO in Asia

• Best ADC Platform Technology

These awards highlight WuXi XDC’s expertise in ADC contract discovery, development and manufacturing, as well as its pioneering platform technologies that support global pharmaceutical partners in advancing ADC/XDC developments.

“We are honored to receive these prestigious awards, which not only reaffirm our team’s relentless pursuit of excellence and innovation but also under score our dedication to delivering world-class services that empower our clients tobring novel therapies to patients worldwide,” said Dr. Jun Hu, WuXi XDC.

Pioneering ADC Innovation and Excellence

The Asia-Pacific Biopharma Excellence Awards celebrate outstanding achievements in bioprocessing, logistics, supply chain management, and clinical trials, honoring industry leaders who are shaping the future of biopharma.

WuXi XDC: A Leading Global CRDMO Specializing in ADCs and Other Bioconjugates

As a fully integrated Contract Research, Development and Manufacturing Organization(CRDMO), WuXi XDC provides comprehensive solutions for ADC/XDC discovery, development, and manufacturing, supporting biopharma/biotech innovators worldwide.

Through its state-of-the-art facilities, cutting-edge bioconjugation technology, and scalable GMP manufacturing capabilities, WuXi XDC enables seamless, high-quality production of ADC/XDCs, helping clients advance their drug pipelines with speed and efficiency.

‍About WuXi XDC

‍WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

For more information about WuXi XDC, please visit: www.wuxixdc.com

‍